Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients
(1992) In Nephron 60(4). p.390-396- Abstract
Anemia is already present in patients with moderate renal failure and is a major cause of the decline in exercise capacity seen in these patients. We examined the effects of erythropoietin (EPO) treatment in 12 predialytic uremic patients (EPO group: mean age 46 ± 12 years; 6 men, 6 women) with a mean glomerular filtration rate (GFR) of 10 ± 4 ml/min x 1.73 m2. These patients were compared to a control group of 8 patients (5 men, 3 women). The observation period was 3 months. The EPO group received 300 U/kg body weight i.v. once a week. The EPO group increased their total hemoglobin (THb) from 323 ± 89 to 466 ± 128 g (p <0.001) and their hemoglobin concentration from 86 ± 8 to 117 ± 11 g/l (p <0.001). Their exercise... (More)
Anemia is already present in patients with moderate renal failure and is a major cause of the decline in exercise capacity seen in these patients. We examined the effects of erythropoietin (EPO) treatment in 12 predialytic uremic patients (EPO group: mean age 46 ± 12 years; 6 men, 6 women) with a mean glomerular filtration rate (GFR) of 10 ± 4 ml/min x 1.73 m2. These patients were compared to a control group of 8 patients (5 men, 3 women). The observation period was 3 months. The EPO group received 300 U/kg body weight i.v. once a week. The EPO group increased their total hemoglobin (THb) from 323 ± 89 to 466 ± 128 g (p <0.001) and their hemoglobin concentration from 86 ± 8 to 117 ± 11 g/l (p <0.001). Their exercise capacity, measured by a standardized exercise test on a bicycle ergometer, increased from 128 ± 45 to 147 ± 57 W (p <0.01). The control group did not change their THb (349 ± 124 and 357 ± 131 g), hemoglobin (93 ± 8 and 94 ± 10 g/l) or exercise capacity (98 ± 49 and 101 ± 50 W) during the observation period. There was a significant correlation between the increase in THb and the increase in exercise capacity in the EPO group (r = 0.81, p <0.005). The GFR was unchanged in both groups (EPO group :10 ± 4 and 10 ± 6 ml/min x 1.73 m2: control group: 8 ± 3 and 8 ± 3 ml/min x 1.73 m2). The median renal plasma flow did not change significantly in either group (EPO group: 42 and 27 ml/ min x 1.73 m2; control group: 34 and 28 ml/min x 1.73 m2). The median filtration fraction, however, increased signifcantly in the EPO group (0.21 to 0.30; p <0.05), while the filtration fraction in the control group was unchanged (0.22 and 0.25; NS). We conclude that erythropoietin treatment increases the THb in predialytic uremic patients, resulting in an improved exercise capacity without affecting GFR.
(Less)
- author
- Clyne, N. LU and Jogestrand, T.
- publishing date
- 1992
- type
- Contribution to journal
- publication status
- published
- keywords
- Erythropoietin, Exercise capacity, Renal function, Uremia
- in
- Nephron
- volume
- 60
- issue
- 4
- pages
- 7 pages
- publisher
- Karger
- external identifiers
-
- scopus:0026523401
- pmid:1584314
- ISSN
- 0028-2766
- language
- English
- LU publication?
- no
- id
- b267c61a-ade5-43ff-b393-762e1699f21a
- date added to LUP
- 2016-08-30 22:05:18
- date last changed
- 2024-01-04 11:46:30
@article{b267c61a-ade5-43ff-b393-762e1699f21a, abstract = {{<p>Anemia is already present in patients with moderate renal failure and is a major cause of the decline in exercise capacity seen in these patients. We examined the effects of erythropoietin (EPO) treatment in 12 predialytic uremic patients (EPO group: mean age 46 ± 12 years; 6 men, 6 women) with a mean glomerular filtration rate (GFR) of 10 ± 4 ml/min x 1.73 m<sup>2</sup>. These patients were compared to a control group of 8 patients (5 men, 3 women). The observation period was 3 months. The EPO group received 300 U/kg body weight i.v. once a week. The EPO group increased their total hemoglobin (THb) from 323 ± 89 to 466 ± 128 g (p <0.001) and their hemoglobin concentration from 86 ± 8 to 117 ± 11 g/l (p <0.001). Their exercise capacity, measured by a standardized exercise test on a bicycle ergometer, increased from 128 ± 45 to 147 ± 57 W (p <0.01). The control group did not change their THb (349 ± 124 and 357 ± 131 g), hemoglobin (93 ± 8 and 94 ± 10 g/l) or exercise capacity (98 ± 49 and 101 ± 50 W) during the observation period. There was a significant correlation between the increase in THb and the increase in exercise capacity in the EPO group (r = 0.81, p <0.005). The GFR was unchanged in both groups (EPO group :10 ± 4 and 10 ± 6 ml/min x 1.73 m<sup>2</sup>: control group: 8 ± 3 and 8 ± 3 ml/min x 1.73 m<sup>2</sup>). The median renal plasma flow did not change significantly in either group (EPO group: 42 and 27 ml/ min x 1.73 m<sup>2</sup>; control group: 34 and 28 ml/min x 1.73 m<sup>2</sup>). The median filtration fraction, however, increased signifcantly in the EPO group (0.21 to 0.30; p <0.05), while the filtration fraction in the control group was unchanged (0.22 and 0.25; NS). We conclude that erythropoietin treatment increases the THb in predialytic uremic patients, resulting in an improved exercise capacity without affecting GFR.</p>}}, author = {{Clyne, N. and Jogestrand, T.}}, issn = {{0028-2766}}, keywords = {{Erythropoietin; Exercise capacity; Renal function; Uremia}}, language = {{eng}}, number = {{4}}, pages = {{390--396}}, publisher = {{Karger}}, series = {{Nephron}}, title = {{Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients}}, volume = {{60}}, year = {{1992}}, }